News About: Pharm. Affairs
Targeted therapy for HER2-negative breast cancer, ‘Ibrance’ acquires approval
Silent for more than ten years. a targeted therapy for Human Epidermal Growth Factor Receptor 2(HER2)-negative breast cancer acquired approval of commercialization in Korea.
On the 29th, the Ministry of Food and Drug...
Well-matched contest in basal insulin market between Sanofi and Novo Nordisk
Competition is getting fiercer in the market of next-generation basal insulin which might replace Lantus. Sanofi and Novo Nordisk are even having a publicity war to show off their companies’ performances.
Novo Nordis...
Kwang Dong’s targeted therapy Afinitor challenges to patent
Kwang Dong Pharmaceutical started to develop a first generic of ‘Afinitor(generic name: everolimus),’ a Novartis’ targeted therapy.
Used to treat diseases such as breast cancer and renal cancer, Afinitor is recording...
Pharmacy circles, Harvoni & Sovaldi are pies in the sky unless having cash power
A phenomenon to avoid Gilead’s hepatitis C treatments which cost millions of wons ‘Harvoni’ and ‘Sovaldi’ is getting intensified. Since both local and hospital pharmacies are avoiding to dispense the drugs, it is unco...
Competition in long-acting schizophrenia injections between Otsuka and Janssen
When it comes to treating schizophrenia, competition among long-acting injections(LAIs) is about to be intensified.
This is because a series of new drug launches are expected for schizophrenia patients who are havin...
Market share of Novo Nordisk’s Tresiba grew twice more in 2nd quarter
The market share of a Novo Nordisk Pharma Korea’s next-generation basal insulin, Tresiba Flextouch Inj(generic name: insulin degludec), was increased by double in the 2nd quarter compared to the one of the 1st quarter...
Will AstraZeneca’s 3 types of antibody be transferred to ‘Alvogen’?
AstraZeneca’s 3 types of antibody are expected to be transferred to Alvogen.
According to the industry concerned on the 26th, the two companies are discussing license transfers of 3 current breast cancer therapies, s...
Cialis generic effect causes slumps on ED drugs altogether
Since a number of Cialis generics were poured out in the market on September last year, existing erectile dysfunction(ED) therapies went into slump together. In the first half of the year, most of the top drugs except...
First NOAC reversal agent Praxbind lands in multiple univ. hospitals
The Boehringer Ingelheim’s first reversal agent for novel oral anticoagulants(NOAC), ‘Praxbind(idarucizumab),’ is promptly landing in large university hospitals after its launch.
After the launch last June, Praxbind ...
“I’m certain CPhI Korea will become a global event within 10 years”
President Han-ki Kim at the Korea Pharmaceutical Traders Association which hosts the largest pharmaceutical exhibition held in Korea and an international event, CPhI Korea, expressed confidence, saying “CPhI Korea wil...
